8-K current report · filed Oct 8, 2026

Perspective Therapeutics, Inc. (CATX) 8-K Current Report: October 8, 2026

Item 8.01Item EX-99.1CATX overview

Short answer

Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA Fast Track Designation granted to PSV359 for advanced FAP-positive solitary fibrous tumors.

Perspective Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA Fast Track Designation granted to PSV359 for advanced FAP-positive solitary fibrous tumors
  • Adult patients with locally advanced unresectable and/or metastatic disease targeted
  • Regulatory designation may enable more frequent FDA interaction and potential expedited development
  • PSV359 remains investigational, with clinical and commercial outcomes still uncertain

Item EX-99.1 · Exhibit EX-99.1

  • FDA Fast Track designation for PSV359 in FAP-positive solitary fibrous tumors, supporting expedited regulatory interaction
  • Rare, serious cancer with limited treatment options, creating potential orphan-disease development opportunity
  • PSV359 remains investigational in ongoing Phase 1/2a study NCT06710756, with safety, tolerability and dose selection still unresolved
  • Fast Track may enable rolling review, Accelerated Approval or Priority Review, but each requires separate FDA criteria
  • Broader FAP-targeted platform potential across multiple solid tumors, balanced against clinical, regulatory and funding risks

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Perspective Therapeutics, Inc. 8-K filings

Get the next CATX 8-K as it lands

Follow CATX for push alerts, or ask the research agent what this filing means.